|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Feb 01, 2013 |
Title |
Intrinsic glioma subtypes in EORTC 26951 (part 2) |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Background: Intrinsic glioma subtypes (IGS) are molecularly similar tumors that can be identified based on unsupervised gene-expression analysis. Here, we have evaluated the clinical relevance of these subtypes within EORTC26951, a randomized phase III clinical trial investigating adjuvant procarbazine, CCNU (lomustine) and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors. Our study is the first to include gene-expression profiles of formalin-fixed and paraffin-embedded (FFPE) clinical trial samples. Methods: Gene-expression profiling was performed in 140 samples: 47 fresh frozen and 93 FFPE, on HU133_Plus_2.0 and HuEx_1.0_st arrays (Affymetrix), respectively. Results: All previously identified six intrinsic glioma subtypes are present in EORTC26951. This confirms that different molecular subtypes are present within a well-defined histological subtype. Intrinsic subtypes are highly prognostic for overall- (OS) and progression-free survival (PFS). They are prognostic for PFS independent of clinical (age, performance, tumor location), molecular (1p19qLOH, IDH1 mutation, MGMT methylation) and histological parameters. Combining known molecular (1p19LOH, IDH1) prognostic parameters with intrinsic subtypes improves outcome prediction (Proportion of Explained Variation 30% v 23%). Specific genetic changes (IDH1, 1p19qLOH and EGFR amplification) segregate into different subtypes. We identified one subtype, IGS-9 (characterized by a high percentage of 1p19qLOH and IDH1 mutations), that especially benefits from PCV chemotherapy. Median OS in this subtype was 5.5 years after radiotherapy (RT) alone v 12.8 years after RT/PCV; P=0.0349; HR 2.18, 95% CI [1.06, 4.50]. Conclusion: Intrinsic subtypes are highly prognostic in EORTC26951 and improve outcome prediction when combined with other prognostic factors. Tumors assigned to IGS-9 benefit from adjuvant PCV
|
|
|
Overall design |
A total of 140 samples were included in this study, profiles of 95 were FFPE derived samples run on exon arrays. 12 samples (part 2) can also be found in GSE16011 (PMID 19920198 and 16357140), and 6 from Oncomine (part 3).
|
|
|
Contributor(s) |
Erdem L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, den Dunnen WF, Teepen JL, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, van den Bent MJ, French PJ |
Citation(s) |
23269986, 24553142 |
|
Submission date |
Dec 21, 2012 |
Last update date |
Feb 27, 2014 |
Contact name |
Pim French |
E-mail(s) |
p.french@erasmusmc.nl
|
Phone |
+31 10 70443 33
|
Organization name |
Erasmus MC
|
Department |
Neurology
|
Lab |
Neurooncology
|
Street address |
Dr Molewaterplein 50
|
City |
Rotterdam |
ZIP/Postal code |
2040CA |
Country |
Netherlands |
|
|
Platforms (1) |
GPL8542 |
Affymetrix GeneChip Human Genome U133 Plus 2.0 Array [CDF: Hs133P_Hs_ENTREZG.cdf] |
|
Samples (28)
|
|
This SubSeries is part of SuperSeries: |
GSE43388 |
Intrinsic glioma subtypes in EORTC 26951 |
|
Relations |
BioProject |
PRJNA185823 |
Supplementary file |
Size |
Download |
File type/resource |
GSE43113_RAW.tar |
146.0 Mb |
(http)(custom) |
TAR (of CEL) |
GSE43113_clinical_data.xlsx.gz |
54.0 Kb |
(ftp)(http) |
XLSX |
Processed data included within Sample table |
|
|
|
|
|